These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29158680)

  • 1. Analysis of the factors affecting the safety of robotic stereotactic body radiation therapy for hepatocellular carcinoma patients.
    Liu X; Song Y; Liang P; Su T; Zhang H; Zhao X; Yuan Z; Wang P
    Onco Targets Ther; 2017; 10():5289-5295. PubMed ID: 29158680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of CyberKnife stereotactic body radiation therapy for hepatocellular carcinoma on hepatic toxicity.
    Liang P; Huang C; Liang SX; Li YF; Huang SX; Lian ZP; Liu JM; Tang Y; Lu HJ
    Onco Targets Ther; 2016; 9():7169-7175. PubMed ID: 27920555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT).
    Scorsetti M; Comito T; Cozzi L; Clerici E; Tozzi A; Franzese C; Navarria P; Fogliata A; Tomatis S; D'Agostino G; Iftode C; Mancosu P; Ceriani R; Torzilli G
    J Cancer Res Clin Oncol; 2015 Jul; 141(7):1301-9. PubMed ID: 25644863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Albumin - bilirubin (ALBI) versus Child-Turcotte-Pugh (CTP) in prognosis of HCC after stereotactic body radiation therapy.
    Su TS; Yang HM; Zhou Y; Huang Y; Liang P; Cheng T; Chen L; Li LQ; Liang SX
    Radiat Oncol; 2019 Mar; 14(1):50. PubMed ID: 30917853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parameters.
    Jung J; Yoon SM; Kim SY; Cho B; Park JH; Kim SS; Song SY; Lee SW; Ahn SD; Choi EK; Kim JH
    Radiat Oncol; 2013 Oct; 8():249. PubMed ID: 24160910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
    Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
    BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualized Adaptive Radiation Therapy Allows for Safe Treatment of Hepatocellular Carcinoma in Patients With Child-Turcotte-Pugh B Liver Disease.
    Jackson WC; Tang M; Maurino C; Mendiratta-Lala M; Parikh ND; Matuszak MM; Dow JS; Cao Y; Mayo CS; Ten Haken RK; Schipper MJ; Cuneo KC; Owen D; Lawrence TS
    Int J Radiat Oncol Biol Phys; 2021 Jan; 109(1):212-219. PubMed ID: 32853708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular carcinoma patients with portal vein thrombosis treated with robotic radiosurgery: Interim results of a prospective study.
    Dutta D; Tatineni T; Yarlagadda S; Gupte A; Reddy SK; Madhavan R; Nair H; Sasidharan A; Kannan R; Pottayil SG; Holla R; Sudhindran S
    Indian J Gastroenterol; 2021 Aug; 40(4):389-401. PubMed ID: 34694581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic outcome and related predictors of stereotactic body radiotherapy for small liver-confined HCC: a systematic review and meta-analysis of observational studies.
    Long Y; Liang Y; Li S; Guo J; Wang Y; Luo Y; Wu Y
    Radiat Oncol; 2021 Apr; 16(1):68. PubMed ID: 33832536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma.
    Jang WI; Kim MS; Bae SH; Cho CK; Yoo HJ; Seo YS; Kang JK; Kim SY; Lee DH; Han CJ; Kim J; Park SC; Kim SB; Cho EH; Kim YH
    Radiat Oncol; 2013 Oct; 8():250. PubMed ID: 24160944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Liver Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma After Segmental Transarterial Radioembolization.
    Hardy-Abeloos C; Lazarev S; Ru M; Kim E; Fischman A; Moshier E; Rosenzweig K; Buckstein M
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):968-976. PubMed ID: 31536781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocellular carcinoma with child Pugh-A Cirrhosis treated with stereotactic body radiotherapy.
    Hasan S; Thai N; Uemura T; Kudithipudi V; Renz P; Abel S; Kirichenko AV
    World J Gastrointest Surg; 2017 Dec; 9(12):256-263. PubMed ID: 29359031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic body radiation therapy in hepatocellular carcinoma: Optimal treatment strategies based on liver segmentation and functional hepatic reserve.
    Wang PM; Chung NN; Hsu WC; Chang FL; Jang CJ; Scorsetti M
    Rep Pract Oncol Radiother; 2015; 20(6):417-24. PubMed ID: 26696781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic body radiotherapy for primary hepatocellular carcinoma.
    Andolino DL; Johnson CS; Maluccio M; Kwo P; Tector AJ; Zook J; Johnstone PA; Cardenes HR
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e447-53. PubMed ID: 21645977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma.
    Cárdenes HR; Price TR; Perkins SM; Maluccio M; Kwo P; Breen TE; Henderson MA; Schefter TE; Tudor K; Deluca J; Johnstone PA
    Clin Transl Oncol; 2010 Mar; 12(3):218-25. PubMed ID: 20231127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication.
    Son SH; Choi BO; Ryu MR; Kang YN; Jang JS; Bae SH; Yoon SK; Choi IB; Kang KM; Jang HS
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1073-80. PubMed ID: 20207492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of gadoxetate disodium-enhanced hepatic MRI for stereotactic body radiotherapy of hepatocellular carcinoma.
    Nakamura Y; Kimura T; Higaki T; Honda Y; Komoto D; Yamagami T; Iida M; Nagata Y; Honda Y; Aikata H; Chayama K; Awai K
    Jpn J Radiol; 2015 Oct; 33(10):627-35. PubMed ID: 26227061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scores of Child-Pugh Classification Impact Overall Survival After Stereotactic Body Radiation Therapy for Primary and Metastatic Liver Tumors.
    Tanaka O; Kojima T; Ohbora A; Makita C; Taniguchi T; Ono K; Matsuo M; Nagata Y
    J Clin Exp Hepatol; 2020; 10(2):101-105. PubMed ID: 32189924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation.
    O'Connor JK; Trotter J; Davis GL; Dempster J; Klintmalm GB; Goldstein RM
    Liver Transpl; 2012 Aug; 18(8):949-54. PubMed ID: 22467602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Stereotactic Body Radiation Therapy Combined With or Without Transcatheter Arterial Chemoembolization for Patients With Small Hepatocellular Carcinoma Ineligible for Resection or Ablation Therapies.
    Kimura T; Aikata H; Doi Y; Imano N; Takeuchi Y; Takahashi I; Nishibuchi I; Katsuta T; Kenjo M; Murakami Y; Awai K; Chayama K; Nagata Y
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818783450. PubMed ID: 29963972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.